Drug Trial Radar · NCT04847232
Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)
Last checked: Nov 20, 2026Latest source record: Jun 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2,690
Actual
Start
Apr 30, 2021
Primary completion
Mar 7, 2024
Study completion Mar 7, 2024
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Apr 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC) on arrhythmia-related cardiovascular outcomes in participants on chronic hemodialysis with recurrent hyperkalemia.
Conditions
- Hyperkalemia
Interventions
Sodium Zirconium Cyclosilicate (SZC)Drug
Powder for oral suspension in a sachet. A dose is titrated in 5 g increments during a period of 4 weeks from 5 g up to 15 g qd on non-dialysis days. Afterward, the dose is adjusted monthly (or more frequent based on clinical judgment) depending on the current potassium value as measured after the long interdialytic interval (LIDI).
SZC PlaceboDrug
Powder for oral suspension in a sachet. A dose is titrated in 5 g increments during a period of 4 weeks from 5 g up to 15 g qd on non-dialysis days. Afterward, the dose is adjusted monthly (or more frequent based on clinical judgment) depending on the current potassium value as measured after the LIDI.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of the Composite of Cardiac Event OutcomesTime frame: From Randomization (Visit 4) up to week 129 (Randomized Study Intervention Phase)
Locations
340 sites in 26 countries. Site status is shown where the registry gives one.
Research Site
Huntsville, Alabama
Research Site
Mesa, Arizona
Research Site
Bakersfield, California
Research Site
Glendale, California
Research Site
Granada Hills, California
Research Site
Lynwood, California
Research Site
San Diego, California
Research Site
Vacaville, California
Research Site
Victorville, California
Research Site
Denver, Colorado
Research Site
Bloomfield, Connecticut
Research Site
Middlebury, Connecticut
Research Site
Newark, Delaware
Research Site
Fort Lauderdale, Florida
Research Site
Tampa, Florida
Research Site
Columbus, Georgia
Research Site
Lawrenceville, Georgia
Research Site
Statesboro, Georgia
Research Site
Nampa, Idaho
Research Site
Iowa City, Iowa
Research Site
Baton Rouge, Louisiana
Research Site
Detroit, Michigan
Research Site
Kalamazoo, Michigan
Research Site
Roseville, Michigan
Research Site
Minneapolis, Minnesota
Research Site
Brookhaven, Mississippi
Research Site
Columbus, Mississippi
Research Site
Tupelo, Mississippi
Research Site
Kansas City, Missouri
Research Site
St Louis, Missouri
Research Site
St Louis, Missouri
Research Site
Las Vegas, Nevada
Research Site
Las Vegas, Nevada
Research Site
Jersey City, New Jersey
Research Site
Manhasset, New York
Research Site
The Bronx, New York
Research Site
Charlotte, North Carolina
Research Site
New Bern, North Carolina
Research Site
Winston-Salem, North Carolina
Research Site
Bethlehem, Pennsylvania
Showing 40 of 340 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.